Literature DB >> 21346421

Early and late outcomes of cardiac operations in patients with cirrhosis: a retrospective survival-rate analysis of 47 patients over 8 years.

Felix Gundling1, Holger Seidl, Laura Gansera, Tibor Schuster, Ellen Hoffmann, Bernhard M Kemkes, Bernd Eichinger, Brigitte Gansera, Wolfgang Schepp, Fabian Schmidtler.   

Abstract

OBJECTIVES: Patients with liver cirrhosis are considered as high-risk population for cardiac surgery. The aim of this study was to review mortality and mid-term outcome of patients with liver cirrhosis requiring coronary artery bypass graft (CABG), valve replacement, or combined procedures.
METHODS: Between July 1997 and December 2006, 47 patients (mean age 65.4 ± 11.7 years) with liver cirrhosis were operated for CABG (21 patients), aortic valve replacement /mitral valve replacement (14 patients), CABG/VR (9 patients) or aortic dissection/tumorexstirpation (3 patients) (group I). Thirty-three patients were classified as Child-Pugh class A (subgroup A), 14 patients as Child-Pugh class B cirrhosis (subgroup B). Postoperative complications/mortality were analyzed retrospectively and compared with a propensity-score pair-matched control group of 47 patients (group II). Follow-up ranged from 0.1 to 11.5 years (mean 3.9 ± 0.25 years) and was complete for 100%.
RESULTS: Necessity of blood products was higher in group I (red cells, fresh frozen plama, platelets; P < 0.01). Chest-tube output (group I 1113 ± 857 vs. group II 849 ± 521; P = 0.15) and re-exploration rate (8.5 vs. 0%; P = 0.11) were slightly accelerated. Ventilation time and ICU-stay was prolonged (P < 0.015). Thirty-day mortality showed 19.1% (group I) versus 8.5% (group II) (P < 0.01), 6.1% (subgroup A) versus 50% (subgroup B) (P < 0.01). Operative risk in subgroup A was not significantly increased compared with control group (P = 0.68). In Child-B operative risk was 15.5-fold higher than in Child-A cirrhosis (P < 0.001). Postcardiotomy syndrome and pleurisy were more frequent in the cirrhosis group (4/47 vs. 0/47; P = 0.11). Actuarial survival after 3, 5 and 8 years was: group I 78.6, 75.6, and 70.2% versus group II 89.1, 85.7, and 85.7% (P = 0.08). Subgroup survival analysis was: group A 90.7, 86.6, and 78.5% versus group B 50, 50, and 50% (P < 0.01).
CONCLUSION: Cardiac surgery can be performed safely in patients with Child-Pugh class A and selected patients with Child-Pugh class B cirrhosis. Mid-term survival-rates within 8 years were not significantly different compared with a propensity-score pair-matched control group without cirrhosis.

Entities:  

Mesh:

Year:  2010        PMID: 21346421     DOI: 10.1097/MEG.0b013e32834059b6

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

1.  Cardiac surgery in patients with liver cirrhosis: risk factors for predicting mortality.

Authors:  Cheng-Hsin Lin; Ron-Bin Hsu
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

2.  Critical care management of the adult patient with congenital heart disease: focus on postoperative management and outcomes.

Authors:  Nathalie Roy
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-02

Review 3.  Influence of cirrhosis in cardiac surgery outcomes.

Authors:  Juan C Lopez-Delgado; Francisco Esteve; Casimiro Javierre; Josep L Ventura; Rafael Mañez; Elisabet Farrero; Herminia Torrado; David Rodríguez-Castro; Maria L Carrio
Journal:  World J Hepatol       Date:  2015-04-18

Review 4.  Revisiting blood transfusion and predictors of outcome in cardiac surgery patients: a concise perspective.

Authors:  Carlos E Arias-Morales; Nicoleta Stoicea; Alicia A Gonzalez-Zacarias; Diana Slawski; Sujatha P Bhandary; Theodosios Saranteas; Eva Kaminiotis; Thomas J Papadimos
Journal:  F1000Res       Date:  2017-02-20

Review 5.  Transcatheter aortic valve implantation in the patients with chronic liver disease: A mini-review and meta-analysis.

Authors:  Xiaochun Ma; Diming Zhao; Jinzhang Li; Dong Wei; Jianlin Zhang; Peidong Yuan; Xiangqian Kong; Jiwei Ma; Huibo Ma; Liangong Sun; Yuman Zhang; Qiqi Jiao; Zhengjun Wang; Haizhou Zhang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.